{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:23:42Z","timestamp":1794263022670,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Prothena Biosciences Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-016-0564-2","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T06:35:23Z","timestamp":1484807723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The burden of amyloid light chain amyloidosis on health-related quality of life"],"prefix":"10.1186","volume":"12","author":[{"given":"Martha","family":"Bayliss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"McCausland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer D.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"564_CR1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ajh.23400","volume":"88","author":"MA Gertz","year":"2013","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol. 2013;88:416\u201325.","journal-title":"Am J Hematol"},{"key":"564_CR2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898\u2013909.","journal-title":"N Engl J Med"},{"key":"564_CR3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O\u2019Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817\u201322.","journal-title":"Blood"},{"key":"564_CR4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","volume":"161","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525\u201332.","journal-title":"Br J Haematol"},{"key":"564_CR5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443200","volume":"135","author":"E Muchtar","year":"2016","unstructured":"Muchtar E, Buadi FK, Dispenzieri A, Gertz MA. Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematol. 2016;135:172\u201390.","journal-title":"Acta Haematol"},{"key":"564_CR6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.094482","volume":"98","author":"G Merlini","year":"2013","unstructured":"Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98:1492\u20135.","journal-title":"Haematologica"},{"key":"564_CR7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924\u201333.","journal-title":"J Clin Oncol"},{"key":"564_CR8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","volume":"139","author":"AD Cohen","year":"2007","unstructured":"Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +\/\u2212 thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007;139:224\u201333.","journal-title":"Br J Haematol"},{"key":"564_CR9","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","volume":"110","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561\u20133.","journal-title":"Blood"},{"key":"564_CR10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","volume":"22","author":"HM Lin","year":"2015","unstructured":"Lin HM, Seldin D, Hui A, Berg D, Dietrich CN, Flood E. The patient\u2019s perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 2015;22:244\u201351.","journal-title":"Amyloid"},{"key":"564_CR11","volume-title":"Health-related quality of life in patients with AL amyloidosis: qualitative interviews with physicians and patients. Presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5\u20138, 2015","author":"MK White","year":"2015","unstructured":"White MK, Bayliss M, Finkel M, Lousada I, Guthrie S. Health-related quality of life in patients with AL amyloidosis: qualitative interviews with physicians and patients. Presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5\u20138, 2015. Orlando: Abstract; 2015."},{"key":"564_CR12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1474515114566737","volume":"15","author":"M Smorti","year":"2016","unstructured":"Smorti M, Guarnieri S, Bergesio F, Perfetto F, Cappelli F. Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: the role of life satisfaction. Eur J Cardiovasc Nurs. 2016;15:269\u201375.","journal-title":"Eur J Cardiovasc Nurs"},{"key":"564_CR13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-011-1309-x","volume":"913","author":"R Caccialanza","year":"2012","unstructured":"Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, et al. Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Ann Hematol. 2012;913:399\u2013406.","journal-title":"Ann Hematol"},{"key":"564_CR14","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","volume":"104","author":"DC Seldin","year":"2004","unstructured":"Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104:1888\u201393.","journal-title":"Blood"},{"key":"564_CR15","volume-title":"User\u2019s Manual for the SF-36v2 Health Survey","author":"ME Maruish","year":"2011","unstructured":"Maruish ME. User\u2019s Manual for the SF-36v2 Health Survey. 3rd ed. Lincoln: QualityMetric, Inc.; 2011.","edition":"3"},{"key":"564_CR16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0895-4356(99)00221-8","volume":"53","author":"CW Lee","year":"2000","unstructured":"Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol. 2000;53:451\u20138.","journal-title":"J Clin Epidemiol"},{"key":"564_CR17","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware Jr","year":"2000","unstructured":"Ware Jr JE. SF-36 health survey update. Spine. 2000;25:3130\u20139.","journal-title":"Spine"},{"key":"564_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care"},{"key":"564_CR19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","volume":"11","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, et al. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet J Rare Dis. 2016;11:119.","journal-title":"Orphanet J Rare Dis"},{"key":"564_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13023-015-0294-x","volume":"10","author":"AM Bosch","year":"2015","unstructured":"Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80.","journal-title":"Orphanet J Rare Dis"},{"key":"564_CR21","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Onco. 2012;30:4541\u20139.","journal-title":"J Clin Onco"},{"key":"564_CR22","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S. Department of Health Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration National Institute of Mental Health Psychopharmacology Research Branch; 1976."},{"key":"564_CR23","unstructured":"Dennis JM, Thomas RK. Documentation for Human Subject Review Committees: GfK Company Information, Past External Review, Confidentiality, and Privacy Protections for Panelists. http:\/\/www.knowledgenetworks.com\/ganp\/irbsupport\/docs\/KN%20Confidentiality%20and%20Privacy%20Protections%20Doc%20for%20IRBs.pdf . Accessed 27 Sept 2016."},{"key":"564_CR24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/hrt.78.2.182","volume":"78","author":"S Cox","year":"1997","unstructured":"Cox S, O\u2019Donoghue AC, McKenna WJ, Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997;78:182\u20137.","journal-title":"Heart"},{"key":"564_CR25","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","volume":"121","author":"G Merlini","year":"2013","unstructured":"Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124\u201330.","journal-title":"Blood"},{"key":"564_CR26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/mcp.2010.0480","volume":"86","author":"SK Kumar","year":"2011","unstructured":"Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86:12\u20138.","journal-title":"Mayo Clin Proc"},{"key":"564_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","volume":"20","author":"M Grogan","year":"2015","unstructured":"Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20:155\u201362.","journal-title":"Heart Fail Rev"},{"key":"564_CR28","volume-title":"Epidemiology: Beyond the Basics","author":"M Szklo","year":"2000","unstructured":"Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg: Aspen Publishers; 2000."},{"key":"564_CR29","volume-title":"Plasma cell disorder other than myeloma: treatment of amyloidosis. Presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5\u20138, 2015","author":"G Merlini","year":"2015","unstructured":"Merlini G. Plasma cell disorder other than myeloma: treatment of amyloidosis. Presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5\u20138, 2015. Orlando: Education Spotlight Session; 2015."},{"key":"564_CR30","unstructured":"Rare Diseases: Common Issues in Drug Development: Guidance for Industry. Silver Spring, MD: US Food and Drug Administration; 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM458485.pdf . Accessed 27 Sept 2016."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T04:17:06Z","timestamp":1601353026000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0564-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]},"article-number":"15"}}